Drug class
18F-labelled amyloid beta PET radiotracer; diagnostic imaging agent
Mechanism of action
Binds fibrillar amyloid beta plaques in the brain. Positron emission tomography detects the radiotracer distribution to estimate the presence or absence of amyloid pathology; it is not a treatment for Alzheimer disease.
General use cases
- PET imaging of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment being evaluated for Alzheimer disease or other causes of cognitive decline; scan results must be interpreted with clinical assessment
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
